What is claimed is:

1. An isolated antibody or an antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus F protein (RSV-F), wherein the antibody has one or more of the following characteristics:
   (a) is a fully human monoclonal antibody;
   (b) interacts with an amino acid sequence comprising amino acid residues ranging from about position 161 to about position 188 of SEQ ID NO: 354;
   (c) interacts with either the serine at position 173 of SEQ ID NO: 354, or the threonine at position 174 of SEQ ID NO: 354, or both the serine at position 173 of SEQ ID NO: 354 and the threonine at position 174 of SEQ ID NO: 354;
   (d) is capable of neutralizing respiratory syncytial virus subtype A and subtype B strains *in vitro;*
   (e) demonstrates the ability to significantly reduce the nasal and/or lung viral load *in vivo* in an animal model of RSV infection; or
   (f) inhibits fusion of the virus to the cell.

2. An isolated antibody or an antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus F protein (RSV-F), wherein the antibody or the antigen-binding fragment thereof interacts with an amino acid sequence comprising amino acid residues ranging from about position 161 to about position 188 of SEQ ID NO: 354.

3. The isolated antibody of claim 2, wherein the antibody is a fully human monoclonal antibody that neutralizes respiratory syncytial virus subtype A and/or subtype B strains *in vitro* and *in vivo*.

4. The isolated antibody or antigen-binding fragment thereof of any of claims 1 through 3, wherein the antibody or the antigen-binding fragment thereof demonstrates the ability to significantly reduce the lung viral load in a mouse model of RSV infection when administered at a dose ranging from about 0.05 mg/kg to about 0.15 mg/kg.

5. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 4, wherein the antibody or the antigen-binding fragment thereof demonstrates a 1-2 logs greater reduction of nasal and/or lung viral titers as compared to palivizumab in a cotton rat model of RSV infection when administered at a dose ranging from about 0.62 mg/kg to about 5.0 mg/kg.

6. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 5, wherein the antibody or the antigen-binding fragment thereof demonstrates an ED_{99} of about 0.15 mg/kg or less when administered in a mouse model of RSV subtype A infection.

7. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 6, wherein the antibody or the antigen-binding fragment thereof demonstrates an ED_{99} of about 0.62 mg/kg or less when administered in a cotton rat model of RSV subtype A infection.

8. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 7, wherein the antibody or the antigen-binding fragment thereof demonstrates an ED_{99} of about 2.5 mg/kg or less when administered in a cotton rat model of RSV subtype B infection.

9. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 8, wherein the antibody or the antigen-binding fragment thereof demonstrates an ED_{99} that is about 2 to 3 fold lower than the ED_{99} for palivizumab or motavizumab.

10. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 9, wherein the antibody or the antigen-binding fragment thereof demonstrates a neutralization potency against one or more subtype A laboratory strains of RSV that is about a 15 to 17 fold improvement over palivizumab, or demonstrates a neutralization potency against one or more subtype A clinical strains of RSV that is about 10 to 22 fold improvement over palivizumab.

11. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 10, wherein the antibody or the antigen-binding fragment thereof demonstrates a neutralization potency against one or more subtype B laboratory strains of RSV that is about a 2 to 5 fold improvement over palivizumab.

12. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 11, wherein the antibody or the antigen-binding fragment thereof demonstrates a neutralization potency against one or more subtype A laboratory strains or subtype A clinical strains of RSV that is about a 0.5 to 2 fold improvement over AM-22.

13. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 12, wherein the antibody or the antigen-binding fragment thereof demonstrates a neutralization potency against one or more subtype B laboratory strains of RSV that is about a 2.5 to 17 fold improvement over AM-22.

14. The isolated antibody or an antigen-binding fragment thereof of any of claims 1 through 13, wherein the antibody or antigen-binding fragment thereof binds specifically to RSV-F with a K_D ranging from 1.0×10^{-7} M to 6.0×10^{-10} M, as measured by surface plasmon resonance.

15. The isolated antibody or antigen-binding fragment thereof of any of claims 1 through 14, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2,

18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338.

16. The isolated antibody or antigen-binding fragment thereof of any of claims 1 through 15, wherein the antibody or antigen-binding fragment comprises a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

17. The isolated antibody or antigen-binding fragment of any of claims 1 through 16, comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: SEQ ID NO: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330 and 338/346.

18. The isolated antibody or antigen-binding fragment of claim 17, comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NO: 274/282 and 338/346.

19. An isolated human antibody or antigen-binding fragment thereof that binds specifically to RSV-F, wherein the antibody comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338; and comprises the three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

20. An isolated human antibody or antigen-binding fragment that specifically binds RSV-F comprising:

(a) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, 280, 296, 312, 328, and 344; and

(b) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288, 304, 320, 336 and 352.

21. The isolated human antibody or antigen-binding fragment of claim 20, further comprising:

(c) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276, 292, 308, 324 and 340;

(d) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, 310, 326 and 342;

(e) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284, 300, 316, 332 and 348; and

(f) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286, 302, 318, 334 and 350.

22. An isolated antibody or antigen-binding fragment thereof that competes for specific binding to RSV-F with an antibody or antigen-binding fragment comprising heavy and light chain sequence pairs selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330 and 338/346.

23. An isolated antibody or antigen-binding fragment thereof that binds the same epitope on RSV-F that is recognized by an antibody comprising heavy and light chain sequence pairs selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330 and 338/346.

24. The isolated antibody of any of claims 1 through 23, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof interacts with at least one amino acid sequence selected from the group consisting of SEQ ID NO: 355 and 356.

25. The isolated antibody of any of claims 1 through 23, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof interacts with at least one residue within residues 161 through 188 of SEQ ID NO: 354.

26. The isolated antibody of any of claims 1 through 23, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof interacts with at least one residue within SEQ ID NO: 355 or SEQ ID NO:356.

27. The isolated antibody of any of claims 1 through 23, or an antigen-binding fragment

thereof, wherein the antibody or antigen-binding fragment thereof interacts with either the serine at position 173 of SEQ ID NO: 354, or the threonine at position 174 of SEQ ID NO: 354, or both the serine at position 173 of SEQ ID NO: 354 and the threonine at position 174 of SEQ ID NO: 354.

28. The isolated antibody or antigen-binding fragment thereof of either claim 2 or 3, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within the heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 274; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within the light chain variable region (LCVR) amino acid sequence of SEQ ID NO: 282.

29. The isolated antibody or antigen-binding fragment thereof of claim 28, comprising:

(a) a HCDR1 domain comprising the amino acid sequence of SEQ ID NO: 276;
(b) a HCDR2 domain comprising the amino acid sequence of SEQ ID NO: 278;
(c) a HCDR3 domain comprising the amino acid sequence of SEQ ID NO: 280;
(d) a LCDR1 domain comprising the amino acid sequence of SEQ ID NO: 284;
(e) a LCDR2 domain comprising the amino acid sequence of SEQ ID NO: 286; and
(f) a LCDR3 domain comprising the amino acid sequence of SEQ ID NO: 288.

30. The isolated antibody of either claim 28 or 29, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof interacts with at least one amino acid sequence selected from the group consisting of SEQ ID NO: 355 and 356.

31. The isolated antibody of either claim 28 or 29, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof interacts with at least one amino acid residue within residues 161 through 188 of SEQ ID NO: 354.

32. The isolated antibody of either claim 28 or 29, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof interacts with at least one amino acid residue within SEQ ID NO: 355 or SEQ ID NO:356.

33. The isolated antibody of either claim 28 or 29, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof interacts with either the serine at position 173 of SEQ ID NO: 354, or the threonine at position 174 of SEQ ID NO: 354, or both the serine at position 173 of SEQ ID NO: 354 and the threonine at position 174 of SEQ ID NO: 354.

34. The isolated antibody of any of claims 1 through 21, wherein the antibody does not

cross-compete for binding to RSV-F with palivizumab, or AM-22.

35. The isolated human antibody of any of claims 1 through 21, or 28 through 34, wherein the antibody does not bind to an epitope on RSV-F ranging from amino acid residue 255 to amino acid residue 276 of SEQ ID NO: 354.

36. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment of any of claims 1 through 35.

37. An expression vector comprising the nucleic acid molecule of claim 36.

38. A host cell comprising the expression vector of claim 37.

39. A method for preventing or treating a respiratory syncytial virus (RSV) infection, or at least one symptom associated with the RSV infection, the method comprising administering an antibody or antigen-binding fragment of any of claims 1 through 35, or a composition comprising an antibody or antigen-binding fragment of any of claims 1 through 35, to a patient in need thereof, such that the RSV infection is prevented, or at least one symptom associated with the infection is alleviated or reduced in number or severity.

40. The method of claim 39, wherein the administering results in prevention of recurrent wheezing in the patient.

41. The method of claim 39, wherein the administering results in prevention of RSV-associated asthma in a child.

42. The method of claim 39, wherein the RSV infection is caused by a subtype A or a subtype B respiratory syncytial virus.

43. The method of claim 39, wherein the patient in need thereof is a patient at high risk of acquiring an RSV infection, or a patient who may experience a more severe form of the RSV infection due to an underlying or pre-existing medical condition.

44. The method of claim 43, wherein the patient is a pre-term infant, a full term infant, a child greater than or equal to one year of age with or without an underlying medical condition (*e.g.* congenital heart disease, chronic lung disease, cystic fibrosis, immunodeficiency, a neuromuscular disorder), an institutionalized or hospitalized patient, or an elderly adult (greater than 65 years of age) with or without an underlying medical condition such as congestive heart failure or chronic obstructive pulmonary disease).

45. The method of either claim 43 or 44, wherein the patient suffers from a condition resulting from a compromised pulmonary, cardiovascular, neuromuscular, or immune system.

46. The method of claim 45, wherein the condition is selected from the group consisting of an abnormality of the airway, a chronic lung disease, a chronic heart disease, a neuromuscular disease that compromises the handling of respiratory secretions and immunosuppression.

47. The method of claim 46, wherein the chronic lung disease is chronic obstructive pulmonary disease (COPD), cystic fibrosis, or bronchopulmonary dysplasia.

48. The method of claim 46, wherein the chronic heart disease is congestive heart failure (CHF), or congenital heart disease.

49. The method of claim 46, wherein the immunosuppression is a result of severe combined immunodeficiency or severe acquired immunodeficiency, or is a result of any other infectious disease or cancerous condition that leads to immunosuppression, or is a result of treatment with immunosuppressant drug therapy or radiation therapy.

50. The method of claim 39, wherein the at least one symptom is selected from the group consisting of fever, nasal congestion, cough, decreased appetite, hypoxia, breathing difficulties (rapid breathing or shortness of breath), wheezing, apnea, dehydration, poor feeding and altered mental status.

51. The method of claim 39, wherein the patient in need thereof is administered the antibody or antigen-binding fragment thereof prophylactically, or therapeutically.

52. The method of claim 39, wherein the antibody or antigen-binding fragment thereof is administered via a route selected from the group consisting of intravenously, intramuscularly, and subcutaneously.

53. The method of claim 39, wherein the antibody or antigen-binding fragment is administered to the patient in combination with a second therapeutic agent.

54. The method of claim 53, wherein the second therapeutic agent is selected from the group consisting of an antiviral agent; a vaccine specific for RSV, a vaccine specific for influenza virus, or a vaccine specific for metapneumovirus (MPV); an siRNA specific for an RSV antigen or a metapneumovirus (MPV) antigen; a second antibody specific for an RSV antigen or a metapneumovirus (MPV) antigen; an anti-IL4R antibody, an antibody specific for an influenza virus antigen, an anti-RSV-G antibody and a NSAID.

55. A pharmaceutical composition comprising any one or more of the isolated antibodies or antigen binding fragments thereof of any of claims 1 through 35 and a pharmaceutically acceptable carrier.

56. The pharmaceutical composition of claim 55 for use in preventing a respiratory syncytial virus (RSV) infection in a patient in need thereof, or for treating a patient suffering from an RSV infection, or for ameliorating at least one symptom or complication associated with the infection, wherein the infection is either prevented, or at least one symptom or complication associated with the infection is prevented, ameliorated, or lessened in severity and/or duration.

57. Use of the pharmaceutical composition of claim 55 in the manufacture of a medicament for preventing a respiratory syncytial virus (RSV) infection in a patient in need thereof, or for treating a patient suffering from an RSV infection, or for ameliorating at least one symptom or complication associated with the infection, wherein the infection is either prevented, or at least one symptom or complication associated with the infection is prevented, ameliorated, or lessened in severity and/or duration.

58. The use according to claim 56 or 57, wherein the patient in need thereof is a patient at high risk of acquiring an RSV infection, or a patient who may experience a more severe form of the RSV infection due to an underlying or pre-existing medical condition.

59. The use according to any of claims 56 through 58, wherein the patient in need thereof is a pre-term infant, a full term infant, a child greater than or equal to one year of age with or without an underlying medical condition (*e.g.* congenital heart disease, chronic lung disease, cystic fibrosis, immunodeficiency, a neuromuscular disorder), an institutionalized or hospitalized patient, or an elderly adult (greater than 65 years of age) with or without an underlying medical condition such as congestive heart failure or chronic obstructive pulmonary disease).

60. The use according to claim 59, wherein the patient suffers from a condition resulting from a compromised pulmonary, cardiovascular, neuromuscular, or immune system.

61. The use according to claim 60, wherein the condition is selected from the group consisting of an abnormality of the airway, a chronic lung disease, a chronic heart disease, a neuromuscular disease that compromises the handling of respiratory secretions and immunosuppression.

62. The use according to claim 61, wherein the chronic lung disease is chronic obstructive pulmonary disease (COPD), cystic fibrosis, or bronchopulmonary dysplasia.

63. The use according to claim 61, wherein the chronic heart disease is congestive heart failure (CHF), or congenital heart disease.

64. The use according to claim 61, wherein the immunosuppression is a result of severe combined immunodeficiency or severe acquired immunodeficiency, or is a result of any other infectious disease or cancerous condition that leads to immunosuppression, or is a result of treatment with immunosuppressant drug therapy or radiation therapy.

65. The use according to claim 56 or 57, wherein the at least one symptom is selected from the group consisting of fever, nasal congestion, cough, decreased appetite, hypoxia, breathing difficulties (rapid breathing or shortness of breath), wheezing, apnea, dehydration, poor feeding and altered mental status.

66. The use according to claim 56 or 57, wherein the patient in need thereof is administered the antibody or antigen-binding fragment thereof prophylactically, or therapeutically.

67. The use according to claim 56 or 57, wherein the composition is administered via a route selected from the group consisting of intravenously, intramuscularly, and subcutaneously.

68. The use according to claim 56 or 57, wherein the composition is administered to the patient in combination with a second therapeutic agent.

69. The use according to claim 68, wherein the second therapeutic agent is selected from the group consisting of an antiviral agent; a vaccine specific for RSV, a vaccine specific for influenza virus, or a vaccine specific for metapneumovirus (MPV); an siRNA specific for an RSV antigen or a metapneumovirus (MPV) antigen; a second antibody specific for an RSV antigen or a metapneumovirus (MPV) antigen; an anti-IL4R antibody, an antibody specific for an influenza virus antigen, an anti-RSV-G antibody and a NSAID.

70. An immunogenic composition comprising an amino acid sequence ranging from about position 161 to about position 188 of SEQ ID NO: 354 and a pharmaceutically acceptable carrier.

71. An immunogenic composition comprising the amino acid sequence of SEQ ID NO: 355 and/or SEQ ID NO: 356 and a pharmaceutically acceptable carrier.

72. The immunogenic composition of either claim 70 or 71, further comprising an adjuvant.

What is claimed is:

1. An isolated human antibody or antigen-binding fragment thereof that binds specifically to RSV-F, wherein the antibody or antigen-binding fragment comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within any one of the heavy chain variable region (HCVR) amino acid sequences selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338; and comprises three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the light chain variable region (LCVR) amino acid sequences selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

2. The isolated human antibody or antigen-binding fragment of claim 1, comprising:

(a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276, 292, 308, 324 and 340**;**

(b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, 310, 326 and 342;

(c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, 280, 296, 312, 328, and 344;

(d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284, 300, 316, 332 and 348;

(e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286, 302, 318, 334 and 350; and

(f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288, 304, 320, 336 and 352.

3. An isolated antibody or antigen-binding fragment thereof that competes for specific binding to RSV-F with an antibody or antigen-binding fragment comprising heavy and light chain sequence pairs selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330 and 338/346, wherein the antibody that competes for specific binding to RSV-F interacts with an epitope comprising an amino acid sequence ranging from about position 161 to about position 188 of SEQ ID NO:354, or interacts with the serine at position 173 of SEQ ID NO: 354, and/or the threonine at position 174 of SEQ ID NO: 354.

4. An isolated antibody or antigen-binding fragment thereof that binds the same epitope on RSV-F that is recognized by an antibody comprising heavy and light chain sequence pairs selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330 and 338/346, wherein the epitope comprises an amino acid sequence ranging from about position 161 to about position 188 of SEQ ID NO:354.

5. The isolated antibody of claim 1, wherein the antibody does not cross-compete for binding to RSV-F with palivizumab, or AM-22.

6. The isolated human antibody of claim 1, wherein the antibody does not bind to an epitope on RSV-F ranging from amino acid residue 255 to amino acid residue 276 of SEQ ID NO: 354.

7. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody is a human recombinant monoclonal antibody.

8. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof interacts with an amino acid sequence comprising amino acid residues ranging from about position 161 to about position 188 of SEQ ID NO: 354.

9. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein

the antibody or antigen-binding fragment thereof interacts with either the serine at position 173 of SEQ ID NO: 354, or the threonine at position 174 of SEQ ID NO: 354, or both the serine at position 173 of SEQ ID NO: 354 and the threonine at position 174 of SEQ ID NO: 354.

10. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322 and 338.

11. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises a light chain variable region (LCVR) amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330 and 346.

12. The isolated antibody or antigen-binding fragment of claim 1, comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330 and 338/346.

13. The isolated antibody or antigen-binding fragment of claim 12, comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 274/282 and 338/346.

14. The isolated antibody or antigen-binding fragment of claim 13, comprising the HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 274/282.

15. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates the ability to significantly reduce the lung viral load in a mouse model of RSV infection when administered at a dose ranging from about 0.05 mg/kg to about 0.15 mg/kg.

16. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates a 1-2 logs greater reduction of nasal and/or lung viral titers as compared to palivizumab in a cotton rat model of RSV infection when administered at a dose ranging from about 0.62 mg/kg to about 5.0 mg/kg.

17. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates an ED_{99} of about 0.15 mg/kg or less when administered in a mouse model of RSV subtype A infection.

18. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates an ED_{99} of about 0.62 mg/kg or less when administered in a cotton rat model of RSV subtype A infection.

19. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates an ED_{99} of about 2.5 mg/kg or less when administered in a cotton rat model of RSV subtype B infection.

20. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates an ED_{99} that is about 2 to 3 fold lower than the ED_{99} for palivizumab or motavizumab.

21. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates a neutralization potency against one or more subtype A laboratory strains of RSV that is about a 15 to 17 fold improvement over palivizumab, or demonstrates a neutralization potency against one or more subtype A clinical strains of RSV that is about 10 to 22 fold improvement over palivizumab.

22. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates a neutralization potency against one or more subtype B laboratory strains of RSV that is about a 2 to 5 fold improvement over palivizumab.

23. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates a neutralization potency against one or more subtype A laboratory strains or subtype A clinical strains of RSV that is about a 0.5 to 2 fold improvement over AM-22.

24. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or the antigen-binding fragment thereof demonstrates a neutralization

potency against one or more subtype B laboratory strains of RSV that is about a 2.5 to 17 fold improvement over AM-22.

25. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof binds specifically to RSV-F with a K_D ranging from 1.0×10^{-7} M to 6.0×10^{-10} M, as measured by surface plasmon resonance.

26. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof has one or more of the following characteristics:

(a) is capable of neutralizing respiratory syncytial virus subtype A and subtype B strains *in vitro;*

(b) demonstrates the ability to significantly reduce the nasal and/or lung viral load *in vivo* in an animal model of RSV infection;

(c) interacts with at least one amino acid residue within SEQ ID NO: 355 or 356; or

(d) inhibits fusion of the virus to the cell.

27. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment of claim 1.

28. An expression vector comprising the nucleic acid molecule of claim 27.

29. A host cell comprising the expression vector of claim 28.

30. A pharmaceutical composition comprising any one or more of the isolated antibodies or antigen binding fragments thereof of claim 1 and a pharmaceutically acceptable carrier.